Diisopropylethylamine → 4-{5-[4-({(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)-2-(3,3-difluoroazetidin-1-yl)pyrimidin-5-yl]-4-methyl-1,3-thiazol-2-yl}-3-methylbenzoic acid
Reaction equation
[F:1][C:2]([F:48])([F:47])[C:3]1[CH:4]=[C:5]([C@H:13]2[O:17][C:16](=[O:18])[N:15]([CH2:19][C:20]3[C:25]([C:26]4[S:30][C:29]([C:31]5[CH:39]=[CH:38][C:34]([C:35]([OH:37])=[O:36])=[CH:33][C:32]=5[CH3:40])=[N:28][C:27]=4[CH3:41])=[CH:24][N:23]=[C:22](S(C)(=O)=O)[N:21]=3)[C@H:14]2[CH3:46])[CH:6]=[C:7]([C:9]([F:12])([F:11])[F:10])[CH:8]=1.[F:49][C:50]1([F:54])[CH2:53][NH:52][CH2:51]1.CCN(C(C)C)C(C)C>C1COCC1>[F:1][C:2]([F:47])([F:48])[C:3]1[CH:4]=[C:5]([C@H:13]2[O:17][C:16](=[O:18])[N:15]([CH2:19][C:20]3[C:25]([C:26]4[S:30][C:29]([C:31]5[CH:39]=[CH:38][C:34]([C:35]([OH:37])=[O:36])=[CH:33][C:32]=5[CH3:40])=[N:28][C:27]=4[CH3:41])=[CH:24][N:23]=[C:22]([N:52]4[CH2:53][C:50]([F:54])([F:49])[CH2:51]4)[N:21]=3)[C@H:14]2[CH3:46])[CH:6]=[C:7]([C:9]([F:12])([F:10])[F:11])[CH:8]=1Participants
Reactant 3
Product 1
Reagents, catalysts & solvents 1
Conditions
- Temperature
- 60 °C
Procedure
To a solution of 4-{5-[4-({(4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-2-oxo-1,3-oxazolidin-3-yl}methyl)-2-(methylsulfonyl)pyrimidin-5-yl]-4-methyl-1,3-thiazol-2-yl}-3-methylbenzoic acid (INTERMEDIATE 54, 200 mg, 0.280 mmol) in THF (5 mL) was added 3,3-difluoroazetidine (129.5 mg, 0.840 mmol) and DIEA (0.244 mL, 1.399 mmol). The reaction mixture was stirred at 60° C. for 15 minutes to see complete conversion by LCMS. The solvent was evaporated, and the residue was purified on reverse phase HPLC, eluting with 10%-100% acetonitrile in water, to give title compound as a slightly yellow solid. LCMS (M+H)+: 728.1. 1H NMR (CDCl3, 500 MHz): δ 8.37 (s, 1H), 8.08 (s, 1H), 8.02 (d, J=8.5 Hz, 1H), 7.93 (s, 1H), 7.90 (d, J=8.5 Hz, 1H), 7.78 (s, 2H), 5.79 (d, J=8.5 Hz, 1H), 4.78 (d, J=17.0 Hz, 1H), 4.58 (m, 4H), 4.42 (m, 3H), 4.08 (d, J=17.0 Hz, 1H), 2.72 (s, 3H), 2.43 (s, 3H), 0.80 (d, J=7.0 Hz, 3H). RTA IC50: 61 nM.
Workup
- customThe solvent was evaporated
- customthe residue was purified on reverse phase HPLC
- washeluting with 10%-100% acetonitrile in water
Sources & evidence
- ORD record
- ord-40733308a63d472eb2e49ea500e8cf34
- Source dataset
- uspto-grants-2016_05
- Patent number
- US09353101B2
Reaction notes
Loading…